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Open Forum Infectious Diseases
MAJOR ARTICLE

Maya Beganovic,1,2 Jaclyn A. Cusumano,1,2 Vrishali Lopes,1 Kerry L. LaPlante,1,2,3,4 and Aisling R. Caffrey1,2,3,5,
1

Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Rhode Island; 2College of Pharmacy, University of Rhode Island, Kingston; 3Center of Innovation in Long-Term
Support Services, Providence Veterans Affairs Medical Center, Rhode Island; 4Warren Alpert Medical School of Brown University, Division of Infectious Diseases, Providence, Rhode Island; 5Brown
University School of Public Health, Providence, Rhode Island

Objective. Beta-lactam antibiotics are recommended as first-line for treatment of methicillin-sensitive Staphylococcus aureus
(MSSA) bacteremia. The objective of this study was to compare effectiveness of anti-MSSA therapies among bacteremia patients
exclusively exposed to 1 antimicrobial.
Method. This was a national retrospective cohort study of patients hospitalized in Veterans Affairs medical centers with MSSA
bacteremia from January 1, 2002, to October 1, 2015. Patients were included if they were treated exclusively with nafcillin, oxacillin,
cefazolin, piperacillin/tazobactam, or fluoroquinolones (moxifloxacin and levofloxacin). We assessed 30-day mortality, time to discharge, inpatient mortality, 30-day readmission, and 30-day S. aureus reinfection. Hazard ratios (HRs) and 95% confidence intervals
(CI) were calculated using propensity-score (PS) matched Cox proportional hazards regression model.
Results. When comparing nafcillin/oxacillin (n = 105) with cefazolin (n = 107), 30-day mortality was similar between groups
(PS matched n = 44; HR, 0.67; 95% CI, 0.11–4.00), as were rates of the other outcomes assessed. As clinical outcomes did not
vary between nafcillin/oxacillin and cefazolin, they were combined for comparison with piperacillin/tazobactam (n = 113) and
fluoroquinolones (n = 103). Mortality in the 30 days after culture was significantly lower in the nafcillin/oxacillin/cefazolin group
compared with piperacillin/tazobactam (PS matched n = 48; HR, 0.10; 95% CI, 0.01–0.78), and similar when compared with
fluoroquinolones (PS matched n = 32; HR, 1.33; 95% CI, 0.30–5.96).
Conclusions. In hospitalized patients with MSSA bacteremia, no difference in mortality was observed between nafcillin/oxacillin and cefazolin or fluoroquinolones. However, higher mortality was observed with piperacillin/tazobactam as compared with
nafcillin/oxacillin/cefazolin, suggesting it may not be as effective as a monotherapy in MSSA bacteremia.
Key words: antibiotic treatment; bloodstream infection; comparative effectiveness; methicillin-susceptible Staphylococcus aureus; Veterans.

INTRODUCTION

Staphylococcus aureus bacteremia is associated with mortality rates as high as 22%–42% [1, 2]. S. aureus can metastasize to other organs, including the heart (ie, endocarditis)
in up to 30%–40% of patients, making appropriate patient
management crucial for the prevention of infection-related
complications and mortality [3]. Antistaphylococcal penicillins
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and cefazolin generally are recognized as preferred treatment
options against MSSA BSIs [4–8]. Furthermore, other betalactams (eg, piperacillin/tazobactam) and fluoroquinolones are
utilized clinically for methicillin-sensitive Staphylococcus aureus (MSSA) bloodstream infections (BSIs), despite the lack of
data supporting this practice.
Several observational comparative effectiveness studies of
antistaphylococcal penicillins and cefazolin for the treatment of
MSSA BSIs have been conducted in the United States, Australia,
New Zealand, Asia, and Canada, ranging from approximately
100 to 7300 patients [4–10]. Although 2 studies favor beta-lactam
therapy over vancomycin for definitive treatment of MSSA BSIs
[10, 11], effectiveness between cefazolin and antistaphylococcal
penicillins is harder to elucidate as several studies have found
no difference in outcomes [4–8] and 2 studies reported better
Comparative Effectiveness With MSSA BSI • ofid • 1
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Comparative Effectiveness of Exclusive Exposure to
Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam,
and Fluoroquinolones Among a National Cohort of
Veterans With Methicillin-Susceptible Staphylococcus
aureus Bloodstream Infection

METHODS
Study Design and Patient Population

We identified a retrospective cohort of patients with MSSApositive blood cultures that were collected January 1, 2002,
to October 1, 2015, during a hospital admission at a Veterans
Affairs (VA) medical center. The following inclusion criteria
were applied: (1) aged 18 years old or older, (2) remained
admitted for more than 2 days, and (3) survived for more than
2 days. The culture collection date served as the index date.
Antibiotic therapies were assessed from the index date through
the discharge date or the first 30 days after culture for admissions
of longer durations. We identified patients treated with a single
antimicrobial therapy for the duration of treatment. Patients receiving combination therapy or with a change in therapy were
excluded. For our study, we identified patients treated with
nafcillin, oxacillin, cefazolin, piperacillin/tazobactam, or fluoroquinolone (moxifloxacin and levofloxacin) monotherapy. To
eliminate the influence of confounding by comedication, we
only included patients treated exclusively with these antibiotics
of interest. Therefore, we excluded patients with changes or
switches in therapy and also excluded patients with other doses
of systemic, empiric, or definitive antimicrobial agents.
Clinical data were obtained from national VA databases
and included International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) diagnostic and
procedure codes during outpatient visits and inpatient stays,
microbiologic and chemistry laboratory data, vital signs, and
pharmacy data, including bar code medication administration
records [14, 15]. Current and past comorbidities were identified
from ICD-9-CM codes. The modified Acute Physiology and
Chronic Health Evaluation (APACHE) III score was utilized to
assess severity of illness, as previously defined [15]. We assessed
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clinical outcomes including all-cause mortality within 30 days
of the first positive MSSA blood culture (index date), length of
hospital stay, length of intensive care unit stay, inpatient mortality, 30-day readmission, and 30-day S. aureus (ie, MSSA and
methicillin-resistant S. aureus [MRSA]) reinfection.
Statistical Analysis

Differences in patient characteristics that were assessed for
the following groups compared: (1) nafcillin/oxacillin versus
cefazolin, (2) nafcillin/oxacillin/cefazolin versus piperacillin/
tazobactam, and (3) nafcillin/oxacillin/cefazolin versus
moxifloxacin/levofloxacin. Therefore, the following steps
were repeated for each comparison. Initial assessment of
differences included chi-square or Fisher exact test for categorical variables, and t test or Wilcoxon rank sum test for continuous variables. Then likelihood ratio testing was used to
identify patient characteristics associated with both exposure
and clinical outcomes. Next, propensity scores (PS) using logistic regression with backwards stepwise elimination were developed. Characteristics, including age, sex, severity of illness,
intensive care stays, and other characteristics independently associated with both exposure and clinical outcomes, were used
to build the propensity score model. For each PS model, the absence of multi-collinearity and goodness of fit were confirmed.
We identified matches using nearest neighbor matching within
a caliper of 0.05. Hazard ratios (HRs) and 95% confidence
intervals (CIs) were calculated using Cox proportional hazards
regression model. A sensitivity analysis adjusting Cox models
for propensity score quintiles was performed. Analyses were
performed with SAS software v. 9.2 (SAS Institute, Cary, NC).
RESULTS

A total of 428 patients were identified and met final inclusion
criteria for analysis. Of them, 105 were in the nafcillin or oxacillin group (24.5%), 107 in the cefazolin group (25.0%), 113 in
the piperacillin/tazobactam (26.4%), and 103 in the fluoroquinolone group (24.1%). We first compared nafcillin/oxacillin with
cefazolin (Table 1). The Charlson comorbidity index was similar
between the nafcillin/oxacillin and cefazolin groups (median, 2
vs 2; P = .61); however, patients in the cefazolin group had higher
rates of chronic kidney disease (41.1% vs 27.6%; P = .04), older age
(mean, 64 vs 60.3; P = .03), and earlier antimicrobial treatment initiation from culture (median, 1 vs 2 days; P = .009) when compared
with nafcillin/oxacillin. Baseline characteristics were balanced between the nafcillin/oxacillin and cefazolin groups via propensity
score matching (nafcillin/oxacillin n = 44, cefazolin n = 44). All
clinical outcomes were similar between the exposure groups, including 30-day mortality (HR, 0.67; 95% CI, 0.11–4.00), discharge
(HR, 0.80; 95% CI, 0.44–1.44) and 30-day readmission (HR, 0.75;
95% CI, 0.26–2.16) (Figure 1). Consequently, the nafcillin/oxacillin and cefazolin were combined (n = 212) to compare preferred

Downloaded from https://academic.oup.com/ofid/article-abstract/6/7/ofz270/5512320 by University of Rhode Island Library user on 26 July 2019

outcomes with cefazolin [9, 12]. A recent meta-analysis of 7
studies, analyzing 1589 patients receiving cefazolin and 2802
patients receiving antistaphylococcal penicillins, reported significantly lower 90-day mortality with cefazolin [12]. Similar
findings were observed in another recent meta-analysis that included 10 studies and 4728 patients [13]. However, these findings
are difficult to interpret due to broad and varying antimicrobial
treatment definitions, including exposures to various antibiotic therapies over the course of infection, which produced
within-treatment-group heterogeneity in the meta-analysis
and limited direct comparison between studies. Therefore, the
objective of this study was to compare effectiveness between
preferred monotherapy treatments (ie, nafcillin, oxacillin, and
cefazolin), and alternative monotherapy treatments, including
piperacillin/tazobactam and fluoroquinolones (levofloxacin
and moxifloxacin) in patients with MSSA BSI. Our cohort
uniquely describes patients treated exclusively with 1 of these
antistaphylococcal antimicrobial agents.

Table 1.

Baseline Demographic and Clinical Characteristics of Patients Receiving Cefazolin and Nafcillin/Oxacillin Therapy
Overall cohort

Propensity-score matched cohort

Nafcillin or
oxacillin (n = 105)

P value

Cefazolin (n = 44)

Nafcillin or
oxacillin (n = 44)

P value

Age, years, mean ± SD

64.0 ± 12.8

60.3 ± 12.4

Male sex, n (%)

105 (98.1)

103 (98.1)

.03

60.8 ± 13.3

62.3 ± 12.3

.57

43 (97.7)

43 (97.7)

Body mass index, kg/m2, mean ± SD

27.9 ± 7.0

28.0 ± 7.3

1.0

.95

27.6 ± 7.9

27.6 ± 7.5

.99

41 (38.3)

35 (33.3)

.45

14 (31.8)

16 (36.4)

.65

2002–2009, n (%)
2010–2015, n (%)

78 (72.9)

86 (81.9)

.12

36 (81.8)

37 (84.1)

.78

29 (27.1)

19 (18.1)

.12

8 (18.2)

7 (15.9)

.78

2 (1–4)

2 (1–4)

.61

2 (1–4)

3 (1.5–4)

.51

Alcoholism

11 (10.3)

15 (14.3)

.37

5 (11.4)

<5 (<11.4)

1.0

Cancer

11 (10.3)

13 (12.4)

.63

<5 (<11.4)

<5 (<11.4)

1.0

Cardiac arrhythmias

27 (25.2)

21 (20.0)

.36

10 (22.7)

10 (22.7)

1.0

8 (7.5)

13 (12.4)

.23

<5 (<11.4)

5 (11.4)

.43

Obese, n (%)

1.0

Year of treatment

Charlson comorbidity index, median (IQR)
Comorbidities, n (%)

Cerebrovascular disease
Diabetes mellitus, complicated

20 (18.7)

13 (12.4)

.21

7 (15.9)

5 (11.4)

.53

Diabetes mellitus, uncomplicated

31 (29.0)

41 (39.1)

.12

13 (29.6)

21 (47.7)

.08

Chronic kidney disease

44 (41.1)

29 (27.6)

.04

18 (40.9)

18 (40.9)

1.0

Dialysis

13 (12.2)

17 (16.2)

.40

8 (18.2)

12 (27.3)

.31
.42

Chronic respiratory disease

17 (15.9)

15 (14.3)

Coagulopathy

<5 (<4.7)

<5 (<4.8)

.74

Coronary heart disease

35 (32.7)

39 (37.1)

.50

1.0

7 (15.9)

10 (22.7)

<5 (<11.4)

<5 (<11.4)

1.0

13 (29.6)

17 (38.6)

.37

Congestive heart failure

18 (16.8)

15 (14.3)

.61

8 (18.2)

7 (15.9)

.78

Fluid and electrolyte disorders

23 (21.5)

27 (25.7)

.47

10 (22.7)

6 (13.6)

.27

Hypertension

65 (60.8)

60 (57.1)

.59

26 (59.1)

28 (63.6)

.66

Peripheral vascular disease

16 (14.9)

11 (10.5)

.33

5 (11.4)

<5 (<11.4)

1.0

9 (8.4)

16 (15.2)

.12

5 (11.4)

7 (15.9)

.53

78 (72.9)

75 (71.4)

.81

34 (77.3)

35 (79.6)

.79

5 (4.7)

6 (5.7)

.73

<5 (<11.4)

<5 (<11.4)

1.0

11 (10.3)

<5 (<4.8)

.07

<5 (<11.4)

<5 (<11.4)

1.0

22 (14–34)

.06

23 (15–33)

20 (13–37)

.55

Liver disease
Community onset infection,b n (%)
Intensive care admission, n (%)
Sepsis, n (%)
APACHE score,b median (IQR)

25.5 (17–37)

Source of infection,c n (%)
Endocarditis

7 (6.5)

8 (7.6)

.76

<5 (<11.4)

<5 (<11.4)

.68

Skin and soft tissue infections

28 (26.2)

18 (17.1)

.11

12 (27.3)

10 (22.7)

.62

Osteomyelitis

12 (11.2)

14 (13.3)

.64

6 (13.6)

6 (13.6)

1.0

Urine

<5 (<4.7)

8 (7.6)

.06

0

5 (11.4)

.06

Respiratory

<5 (<4.7)

<5 (<4.8)

.68

<5 (<11.4)

<5 (<11.4)

1.0

Surgical site

6 (5.6)

<5 (<4.8)

.28

<5 (<11.4)

<5 (<11.4)

1.0

Chronic ulcer

8 (7.5)

<5 (<4.8)

.25

<5 (<11.4)

<5 (<11.4)

1.0

.41

6 (13.6)

6 (13.6)

1.0

0

0

—

2 (0.5–3.5)

2.5 (0–4)

.68

7 (4–14)

7 (5–16)

.41

Prior healthcare exposures, n (%)
Hospitalization prior 30d

14 (13.1)

18 (17.1)

Nursing home prior 30d

<5 (<4.7)

<5 (<4.8)

Time to antimicrobial initiation from culture,
median days (IQR)

1 (0–3)

2 (0–4)

.009

Inpatient antimicrobial duration, median
days (IQR)

8 (5–14)

9 (6–16)

.14

1.0

Abbreviations: APACHE, acute physiology and chronic health evaluation; IQR, interquartile range; SD, standard deviation.
a

Culture-confirmed source of infection.

b

With missing values.

c

Within 48 hours of index culture.

treatment options with piperacillin/tazobactam (n = 113) and
fluoroquinolones (n = 103), respectively.
The piperacillin/tazobactam group (n = 113), compared with
the nafcillin/oxacillin/cefazolin group (n = 212), was older (66.6
vs 62.2 years, P = .003), with higher comorbidity scores (3 vs 2,

P = .0001) and APACHE scores (34.5 vs 24.0, P < .0001; Table
2). Intensive care unit admissions (13.3% vs 5.2%, P = .01), and
previous hospitalizations (24.8% vs 15.1%, P = .03) were more
common in the piperacillin/tazobactam group, with significant
variations in infection source. These baseline characteristics
Comparative Effectiveness With MSSA BSI • ofid • 3
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Cefazolin (n = 107)

Characteristics

Outcomes
30-day mortality
14-day mortality
Inpatient mortality
Discharge
30-day readmission

Nafcillin/Oxacillin
2/44 (4.6)
0/44 (0)
1/44 (2.3)
43/44(97.7)
9/43 (20.9)
4/43 (9.3)

Cefazolin
3/44 (6.8)
3/44 (6.8)
3/44 (6.8)
41/44 (93.2)
8/41 (19.5)
0/41 (0)

HR (95% Cl)

Sooner
outcomes in
Cefazolin

Sooner outcomes
in Nafcillin/
Oxacillin

0.67 (0.11 – 4.0)
*_
*_
0.80 (0.44–1.44)
0.75 (0.26 – 2.16)
*_
0

1

HR 2

3

4

Figure 1. Clinical Outcomes in Propensity-Matched Cefazolin-Treated and Nafcillin/Oxacillin-Treated Patients With Methicillin-Susceptible Staphylococcus aureus
Bacteremiaa.a The propensity score was derived from an unconditional logistic regression model and controlled for the variables listed in Supplementary Table S4. The asterisk symbol denotes that the sample size (n) was too small.

were balanced via a propensity score model (nafcillin/oxacillin/
cefazolin n = 48, piperacillin/tazobactam n = 48) and are further detailed in Table 2. In the propensity-score matched cohort, time to 30-day mortality was significantly higher in the
piperacillin/tazobactam group than the preferred treatment
group (HR, 0.10; 95% CI, 0.01–0.78; Figure 2). Although time
to antimicrobial initiation from culture and duration of therapy
were included in the propensity score model, they remained
significantly different in the matched groups. In a sensitivity
analysis, inclusion of these variables in the Cox proportional
hazards model did not change the effect estimates.
Comorbidity burden was similar between the fluoroquinolone group (moxifloxacin and levofloxacin n = 103) and the preferred treatment group (nafcillin/oxacillin/cefazolin n = 212;
Table 3). However, fluoroquinolone-treated patients were older
(69 vs 62.2 years, P < .0001), with higher APACHE scores
(32 vs 24, P = .0002). After balancing patient characteristics
(nafcillin/oxacillin/cefazolin n = 32, moxifloxacin/levofloxacin
n = 32), no differences in time to mortality were observed between fluoroquinolones and nafcillin/oxacillin/cefazolin in the
propensity-score matched cohort (HR, 1.33; 95% CI, 0.30–5.96;
Figure 2). Similar results across all comparison groups were
observed in sensitivity analyses adjusted by propensity score
quintiles (Supplementary Tables S1 to S3).
DISCUSSION

We compared clinical outcomes among patients with MSSA
bacteremia exclusively treated with nafcillin/oxacillin, cefazolin,
piperacillin/tazobactam, or fluoroquinolone monotherapy
during their hospital stay. Overall, our findings are similar to
published observational studies, with additional insight regarding the use piperacillin/tazobactam in MSSA bacteremia.
Similar to previously published observational studies, we
found that cefazolin effectiveness was not significantly different
from antistaphylococcal penicillins (ie, cloxacillin, flucloxacillin,
4 • ofid • Beganovic et al

and nafcillin) [4, 5, 7, 8]. In contrast with our findings, several studies have reported improved clinical outcomes with
cefazolin [9, 12, 13]. This discrepancy may be due to differences
in inclusion criteria surrounding antimicrobial exposure during
treatment, including safety as an outcome and a potential inoculum effect. Our study preselected a unique cohort of patients
that received only nafcillin/oxacillin, cefazolin, piperacillin/
tazobactam, or fluoroquinolones throughout their entire
hospitalization.
A retrospective cohort conducted in the VA population
compared mortality among MSSA bacteremia patients receiving definitive treatment with nafcillin or oxacillin (n = 2004)
versus cefazolin (n = 1163) from 2003–2010 [9]. In contrast to
our study, the authors found that mortality was higher in the
nafcillin/oxacillin group versus the cefazolin group at 30 days
(10% vs 15%; adjusted HR, 0.63; 95% CI, 0.51–0.78; P < .001),
and at 90 days (25% vs 20%; adjusted HR, 0.77; 95% CI, 0.66–
0.90; P = .001), concluding that cefazolin may be preferred over
nafcillin/oxacillin. The reason for the differences between our
study and this study may be a result of the additional antibiotics
used during both empiric therapy and concomitant antibiotic use. In this other VA study, definitive therapy was defined
as receipt of nafcillin, oxacillin, or cefazolin between 4 and
14 days after culture collection. This treatment definition did
not account for empiric therapy or concomitant therapy [9, 11].
Further, it is unclear whether patients receiving as little as 1 day
of nafcillin, oxacillin, or cefazolin were included in these treatment groups as duration of therapy was not discussed in the
article.
A recently published meta-analysis, which included studies
utilizing various definitions of definitive treatment, found
that 90-day mortality was less likely in patients who received cefazolin compared with antistaphylococcal penicillins
(nafcillin, oxacillin, or cloxacillin; odds ratio [OR], 0.63; 95%
CI, 0.41–0.99) [12]. However, the limitations of this metaanalysis significantly affect the applicability of the findings in
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30-day S. aureus re-infection

No. of events/No. of patients (%)

Table 2.

Baseline Demographic and Clinical Characteristics of Patients Receiving Piperacillin/Tazobactam and Nafcillin/Oxacillin/Cefazolin Therapy
Overall cohort

Propensity-score matched cohort

Characteristics

Piperacillin/
tazobactam
(n = 113)

Nafcillin or oxacillin or
cefazolin (n = 212)

P value

Piperacillin/
tazobactam (n = 48)

Nafcillin or oxacillin or
cefazolin (n = 48)

P value

Age, years, mean ± SD

.69

62.2 ± 12.7

.003

64.4 ± 13.8

63.3 ± 13.0

111 (98.2)

208 (98.1)

1.0

48 (100)

47 (97.9)

1.0

Body mass index, kg/m2, mean ± SD

26.9 ± 7.2

27.9 ± 7.1

.21

26.8 ± 7.6

27.0 ± 6.0

.90

Obese, n (%)

38 (33.6)

76 (35.9)

.69

16 (33.3)

16 (33.3)

1.0

2002–2009, n (%)

76 (67.3)

164 (77.4)

.05

36 (75.0)

36 (75.0)

1.0

2010–2015, n (%)

37 (32.7)

48 (22.6)

.05

12 (25.0)

12 (25.0)

1.0

3 (2–5)

2 (1–4)

.0001

3 (2–4)

2 (1–5)

.34

Year of treatment

Charlson comorbidity index, median (IQR)
Comorbidities, n (%)
Alcoholism

12 (10.6)

26 (12.3)

.66

7 (14.6)

7 (14.6)

1.0

Cancer

22 (19.5)

24 (11.3)

.05

8 (16.7)

7 (14.6)

.78

Cardiac arrhythmias

21 (18.6)

48 (22.6)

.39

7 (14.6)

7 (14.6)

1.0

9 (8.0)

21 (9.9)

.56

5 (10.4)

<5 (<10.4)

1.0

Cerebrovascular disease
Diabetes mellitus, complicated

37(32.7)

33 (15.6)

.0003

13 (27.1)

10 (20.8)

.47

Diabetes mellitus, uncomplicated

48 (42.5)

72 (34.0)

.13

19 (39.6)

17 (35.4)

.67

Chronic kidney disease

41 (36.3)

73 (34.4)

.74

14 (29.2)

16 (33.3)

.66

7 (6.2)

30 (14.2)

.03

<5 (<10.4)

5 (10.4)

.71

Chronic respiratory disease

22 (19.5)

32 (15.1)

.31

5 (10.4)

6 (12.5)

.75

Coagulopathy

10 (8.9)

8 (3.8)

.06

5 (10.4)

<5 (<10.4)

.44

Coronary heart disease

29 (25.7)

74 (34.9)

.09

12 (25.0)

11 (22.9)

.81

Congestive heart failure

26 (23.0)

33 (15.6)

.10

9 (18.8)

5 (10.4)

.25

Fluid and electrolyte disorders

42 (37.2)

50 (23.6)

.01

12 (25.0)

14 (29.2)

.65
.39

Dialysis

Hypertension

76 (67.3)

125 (59.0)

.14

34 (70.8)

30 (62.5)

Peripheral vascular disease

24 (21.2)

27 (12.7)

.04

10 (20.8)

5 (10.4)

.16

Liver disease

10 (8.9)

25 (11.8)

.42

5 (10.4)

<5 (<10.4)

.71

Community onset infection, b n (%)

81 (71.7)

153 (72.2)

.93

33 (68.8)

36 (75.0)

.50

Intensive care admission, n (%)

15 (13.3)

11 (5.2)

.01

<5 (<10.4)

<5 (<10.4)

.36

Sepsis, n (%)
APACHE score,b median (IQR)

8 (7.1)

15 (7.1)

.99

<5 (<10.4)

8 (16.7)

.03

34.5 (22–52)

24.0 (15–37)

<.0001

31 (18–44)

24 (18–38)

.27
.24

Source of infection,c n (%)
0

15 (7.1)

.004

0

<5 (<10.4)

Skin and soft tissue infections

Endocarditis

38 (33.6)

46 (21.7)

.02

16 (33.3)

16 (33.3)

1.0

Osteomyelitis

13 (11.5)

26 (12.3)

.84

6 (12.5)

9 (18.8)

.40

Urine

13 (11.5)

10 (4.7)

.02

<5 (<10.4)

<5 (<10.4)

1.0

Respiratory

10 (8.9)

6 (2.8)

.02

<5 (<10.4)

<5 (<10.4)

1.0

Surgical site

<5 (<4.4)

8 (3.8)

.50

<5 (<10.4)

<5 (<10.4)

.36

Chronic ulcer

24 (21.2)

12 (5.7)

<.0001

9 (18.8)

6 (12.5)

.40

Hospitalization prior 30d

28 (24.8)

32 (15.1)

.03

16 (33.3)

12 (25.0)

.37

Nursing home prior 30d

<5 (<4.4)

<5(<2.4)

.61

<5 (<10.4)

<5 (<10.4)

1.0

Time to antimicrobial initiation from culture, median days (IQR)

0 (0–1)

2 (0–4)

<.0001

0 (0–1)

1 (0–2)

.02

Inpatient antimicrobial duration, median
days (IQR)

5 (3–9)

8.5 (5–14.5)

<.0001

5 (3–10)

10.5 (5–17.5)

.001

Prior healthcare exposures, n (%)

Abbreviations: APACHE, acute physiology and chronic health evaluation; IQR, interquartile range; SD, standard deviation.
a

Culture-confirmed source of infection.

b

With missing values.

c

Within 48 hours of index culture.

clinical practice. For example, only 2 of the 7 included studies
identified a decreased risk of mortality with cefazolin. One was
a small, prospective observational study conducted in South
Korea that reported a higher discontinuation rate with nafcillin

due to side effects. The second study that found a reduction in
mortality with cefazolin was the aforementioned 2003–2010
VA study [9] that utilized broad exposure definitions. This was
the largest and most heavily weighted study included in the
Comparative Effectiveness With MSSA BSI • ofid • 5
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66.6 ± 12.9

Male sex, n (%)

Outcomes

Sooner outcomes in Sooner outcomes in
piperacillin/tazobactam nafcillin/oxacillin/
HR (95%CI)
or fluoroquinolones cefazolin

Nafcillin/oxacillin/cefazolin

Fluoroquinolone or
piperacillin/tazobactam

1/48 (2.1)
4/32 (12.5)

10/48 (20.8)
3/ 32 (9.4)

0.10 (0.01– 0.78)
1.33 (0.30– 5.96)

0/48 (0)
3/32 (9.4)

8/48 (16.7)
2/32 (6.3)

*–
1.5 (0.25– 8.98)

1/48 (2.1)
3/32 (9.4)

9/48 (18.8)
4/32 (12.5)

*–
0.50 (0.05– 5.51)

47/48 (97.9)
29/ 32 (90.6)

39/48 (81.3)
28/32 (87.5)

0.87 (0.48–1.58)
0.72 (0.35– 1.47)

8/47 (17.2)
6/29 (20.7)

10/39 (25.6)
1/28 (3.6)

0.50 (0.17–1.46)
*–

2/47 (4.3)
1/29 (3.5)

4/39 (10.3)
1/28 (3.6)

0.5 (0.09–2. 73)
1.0 (0.06–16.0)
0

1 HR 2

3

4

Figure 2. Clinical Outcomes in Propensity-Matched Nafcillin/Oxacillin/Cefazolin-Treated and Piperacillin/Tazobactam- or Fluoroquinolone-Treated Patients With MethicillinSusceptible Staphylococcus aureus Bacteremiaa. aThe propensity score was derived from an unconditional logistic regression model and controlled for the variables listed in
Supplementary Table S4. The asterisk symbol denotes that the sample size (n) was too small.

meta-analysis, accounting for 73.2% of the cefazolin patients
and 71.5% of the antistaphylococcal penicillin [12]. A second
meta-analysis evaluated 10 studies with similar results and
limitations; however, a subgroup analysis excluding the 2010
VA study [9] was performed and a mortality benefit favoring
cefazolin over antistaphylococcal penicillins remained (risk
ratio [RR], 0.74; 95% CI, 0.58–0.94) [13]. Our study differed,
as we exclusively assessed monotherapy, presuming that empiric and concomitant therapies influence clinical outcomes.
Differences in exposure definitions across studies make direct
comparisons challenging and contribute to the limited applicability of the meta-analysis results.
Although our study did not evaluate safety, it is important to
note that in addition to cefazolin demonstrating greater safety
compared with nafcillin/oxacillin in several studies [6, 16–24],
nafcillin treatment may be associated with higher adverse events
rates than oxacillin [25, 26]. Conversely, increased 30-day allcause mortality with cefazolin has been reported in high inoculum MSSA infections compared with standard inoculum
infections (risk ratio [RR], 2.65; 95% CI, 1.10–6.42; P = .03)
[27]. This is likely due to S. aureus beta-lactamase production.
Initially recognized in the late 1960s with 4 distinct serotypes
(A, B, C, and D) expressing blaZ enzymes [28, 29], type A blaZ
appears to have high affinity for deactivating cefazolin via hydrolysis. Although hydrolysis may be overcome in standard
infections (ie, 5 × 105 CFU/mL), treatment failure in highinoculum infections (ie, >5 × 107 CFU/mL) has been described
[27, 30, 31]. Therefore, inoculum effect (ie, complicated
6 • ofid • Beganovic et al

bacteremia, with foci of infection) should be considered in
patients that are not clinically improving or are decompensating
while on cefazolin [27, 32]. Additionally, the presence of type A,
B, C, and D blaZ enzymes vary geographically and should be
considered when selecting an antistaphylococcal penicillin over
cefazolin. We only assessed patients without changes in therapy
and, therefore, included patients who tolerated monotherapy
with nafcillin, oxacillin, cefazolin, piperacillin/tazobactam, or
fluoroquinolones without significant adverse effects leading to
treatment discontinuation.
Of interest, 30-day mortality was significantly higher for
patients receiving piperacillin/tazobactam compared with
nafcillin, oxacillin, or cefazolin in our study. Our findings are
consistent with a previously published retrospective singlecenter cohort study evaluating empiric and definitive therapy
for MSSA bacteremia among patients receiving a beta-lactam
antimicrobial therapy within 48 hours after blood culture collection [33]. Investigators from this non-US–based
study identified higher mortality among patients receiving
beta-lactams/beta-lactam inhibitors (BLBLIs) empirically
for MSSA bacteremia (OR, 2.68; 95% CI, 1.23–5.85) [33].
Based on empiric therapy, they observed a mortality benefit in patients initially treated with oxacillin or cefazolin
compared with cefuroxime, ceftriaxone, or cefotaxime. For
definitive therapy, it was concluded that cefazolin was not
significantly different from oxacillin (OR, 0.91; 95% CI,
0.47–1.77). Overall, their observations indicate that although
cefazolin may be a safe and effective alternative to oxacillin,
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30-day mortality
Piperacillin/tazobactam
Fluoroquinolones
14-day mortality
Piperacillin/tazobactam
Fluoroquinolones
Inpatient mortality
Piperacillin/tazobactam
Fluoroquinolones
Discharge
Piperacillin/tazobactam
Fluoroquinolones
30-day readmission
Piperacillin/tazobactam
Fluoroquinolones
30-day S. aureus re-infection
Piperacillin/tazobactam
Fluoroquinolones

No. of events/No. of patients (%)

Table 3.

Baseline Demographic and Clinical Characteristics of Patients Receiving Fluoroquinolones and Nafcillin/Oxacillin/Cefazolin Therapy
Overall cohort

Characteristics
Age, years, mean ± SD

Propensity-score matched cohort

Moxifloxacin or
levofloxacin (n = 103)

Nafcillin or oxacillin
or cefazolin (n = 212)

P value

Moxifloxacin or
levofloxacin (n = 32)

Nafcillin or oxacillin or
cefazolin (n = 32)
P value

62.2 ± 12.7

<.0001

71.3 ± 13.7

67.1 ± 15.3

.25

100 (97.1)

208 (98.1)

.69

32 (100)

30 (93.8)

.49

Body mass index, kg/m2, mean ± SD

27.0 ± 7.0

27.9 ± 7.1

.30

27.0 ± 6.4

28.7 ± 7.5

.34

Obese, n (%)

27 (26.2)

76 (35.9)

.09

9 (28.1)

11 (34.4)

.59

2002–2009, n (%)

86 (83.5)

164 (77.4)

.21

28 (87.5)

26 (81.3)

.49

2010–2015, n (%)

17 (16.5)

48 (22.6)

.21

<5 (<15.6)

6 (18.8)

.49

2 (1–5)

2 (1–4)

.36

2.5 (2–5)

2.5 (1.5–4.5)

.55

Year of treatment

Charlson comorbidity index, median (IQR)
Comorbidities, n (%)
Alcoholism

9 (8.7)

26 (12.3)

.35

<5 (<15.6)

<5 (<15.6)

1.0

21 (20.4)

24 (11.3)

.03

6 (18.8)

7 (21.9)

.76

Cardiac arrhythmias

28 (27.2)

48 (22.6)

.38

10 (31.3)

11 (34.4)

.79

Cerebrovascular disease

14 (13.6)

21 (9.9)

.33

8 (25.0)

<5 (<15.6)

.10

Diabetes mellitus, complicated

19 (18.5)

33 (15.6)

.52

<5 (<15.6)

6 (18.8)

.49

Diabetes mellitus, uncomplicated

32 (31.1)

72 (34.0)

.61

12 (37.5)

11 (34.4)

.79

Chronic kidney disease

24 (23.3)

73 (34.4)

.04

11 (34.4)

12 (37.5)

.79

7 (6.8)

30 (14.2)

.06

<5 (<15.6)

5 (15.6)

.71

Chronic respiratory disease

39 (37.9)

32 (15.1)

<.0001

10 (31.3)

6 (18.8)

.25

Coagulopathy

<5 (<4.9)

8 (3.8)

.28

0

<5 (<15.6)

1.0

Coronary heart disease

34 (33.0)

74 (34.9)

.74

13 (40.6)

12 (37.5)

.80

Congestive heart failure

19 (18.5)

33 (15.6)

.52

9 (28.1)

8 (25.0)

.78

Fluid and electrolyte disorders

39 (37.9)

50 (23.6)

.01

10 (31.3)

11 (34.4)

.79

Hypertension

55 (53.4)

125 (59.0)

.35

21 (65.6)

18 (56.3)

.44

Peripheral vascular disease

9 (8.7)

27 (12.7)

.30

6 (18.8)

5 (15.6)

.74

Liver disease

7 (6.8)

25 (11.8)

.17

<5 (<15.6)

<5 (<15.6)

1.0

Community onset infection,b n (%)

76 (73.8)

153 (72.2)

.76

22 (68.8)

19 (59.4)

.43

Intensive care admission, n (%)

<5 (<4.9)

11 (5.2)

.56

<5 (<15.6)

<5 (<15.6)

1.0

Sepsis, n (%)

<5 (<4.9)

15 (7.1)

.26

<5 (<15.6)

<5 (<15.6)

1.0

32 (23- 40)

24 (15–37)

.0002

29 (21- 38)

30 (18–44)

.95

Cancer

Dialysis

APACHE score,b median (IQR)
Source of infection,c n (%)
Endocarditis

0

15 (7.1)

.003

0

<5 (<15.6)

.49

Skin and soft tissue infections

14 (13.6)

46 (21.7)

.09

<5 (<15.6)

<5 (<15.6)

.67

Osteomyelitis

<5 (<4.9)

26 (12.3)

.0008

0

<5 (<15.6)

.11

Urine

19 (18.5)

10 (4.7)

<.0001

<5 (<15.6)

<5 (<15.6)

1.0

Respiratory

22 (21.4)

6 (2.8)

<.0001

<5 (<15.6)

<5 (<15.6)

1.0

Surgical site

<5 (<4.9)

8 (3.8)

.28

0

0

—

Chronic ulcer

8 (7.8)

12 (5.7)

.47

<5 (<15.6)

<5 (<15.6)

1.0

.90

6 (18.8)

5 (15.6)

.74

0

0

—

Prior healthcare exposures, n (%)
Hospitalization prior 30d

15 (14.6)

32 (15.1)

Nursing home prior 30d

<5 (<4.9)

<5 (<2.4)

Time to antimicrobial initiation from culture, median days (IQR)

0 (0–1)

2 (0–4)

<.0001

1 (0–3)

1.5 (0–3.5)

.35

Inpatient antimicrobial duration, median
days (IQR)

5 (3–8)

8.5 (5–14.5)

<.0001

5 (4–11.5)

7 (5–10)

.27

1.0

Abbreviations: APACHE, acute physiology and chronic health evaluation; IQR, interquartile range; SD, standard deviation.
a

Culture-confirmed source of infection.

b

With missing values.

c

Within 48 hours of index culture.

other beta-lactams, including second and third generation
cephalosporins and BLBLIs, may be associated with higher
mortality. Although conflicting data exist [34, 35], other
studies have observed poor outcomes associated with second
and third generation cephalosporins [36–38].

A possible explanation for the increased mortality we
observed with piperacillin/tazobactam may be due to the inability of tazobactam to induce staphylococcal types A and C
beta-lactamases, both of which are associated with elevated
minimum inhibitory concentrations (MIC), in addition to
Comparative Effectiveness With MSSA BSI • ofid • 7
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69.0 ± 13.7

Male sex, n (%)
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by comedication is a major concern with existing comparative effectiveness research in infectious diseases. We, therefore, utilized a highly specific exposure definition to overcome
this problem. However, because antibiotic monotherapy was
not commonly used, sample sizes were low for some of the
exposure-outcome associations assessed. This resulted in several wide confidence interval ranges, which affected the ability
to detect small differences between groups. Moreover, information on source control, time to blood culture clearance, total duration of therapy, doses used, and routes of administration for
fluoroquinolones (ie, intravenous versus oral) were not available. Our findings are supported by other published studies
that have concluded cefazolin is similar to antistaphylococcal
penicillins, and piperacillin/tazobactam may be sub-optimal to
treat MSSA bacteremia [4, 5, 7, 8, 10].
S. aureus bacteremia can metastasize, making it difficult
to eradicate and leading to high mortality rates [1, 2]. Our
comparative effectiveness study demonstrated similar clinical outcomes between nafcillin, oxacillin, cefazolin, and
fluoroquinolones. However, 30-day mortality was higher in
patients receiving piperacillin/tazobactam monotherapy. This
observed higher mortality may be a result of the beta-lactam
inoculum effect providing clinical relevance of this phenomenon previously described by in vitro data [32]. We observed
higher mortality rates among patients treated exclusively with
piperacillin-tazobactam, suggesting it may not be as effective as monotherapy in MSSA bacteremia. Further studies are
warranted to guide provider decisions regarding empiric and
definitive therapy in MSSA bacteremia, including the effect of
discontinuation of piperacillin-tazobactam as empiric therapy.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
the authors, so questions or comments should be addressed to the corresponding author.
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an inoculum effect [32, 39, 40]. A recent study evaluated 302
MSSA isolates and found increased MICs with increased bacterial inoculum [32]. MICs exceeded susceptibility breakpoints
among BLBLIs, including piperacillin/tazobactam, with significant increases in mean MIC between high and standard
inocula (high inoculum, 48.14 ± 4.08 vs standard inoculum,
2.04 ± 0.08 mg/L; P < .001). The inoculum effect for piperacillin/
tazobactam exposure also is associated with presence of type
C blaZ beta-lactamase enzymes 87.8% of the time versus 8.8%
non-type C (P < .001) [32]. Type C enzymes bind more tightly
to piperacillin/tazobactam than type A enzymes and can lead to
a subsequently more pronounced deactivation [40]. Prevalence
of type C enzymes are as high as 46%–53% nationally and internationally [31, 41].
Interestingly, we did not observe a difference between
nafcillin, oxacillin, or cefazolin when compared with
fluoroquinolones (levofloxacin and moxifloxacin). Studies
evaluating fluoroquinolones for MSSA bacteremia are limited,
and often evaluate MRSA [42, 43], which is not a recommended
treatment option [44]. A prospective, randomized, openlabel multicenter trial that compared an oral fluoroquinolone
(fleroxacin) plus rifampin to standard therapy (parenteral
flucoxacillin or vancomycin) for staphylococcal infections
(not exclusively MSSA), found that oral treatment was similar to parenteral therapy [43]. Although this may be because fluoroquinolones have excellent oral bioavailability and
tissue penetration, the comparator in this study is not a preferred treatment for MSSA [43]. Safety concerns should be
considered prior to selecting fluoroquinolones as a treatment
for MSSA bacteremia, including the high risk of developing
a Clostridiodes difficile infection [45], as well as manufacturer
and Food and Drug Administration (FDA)-recognized adverse
events, including, but not limited to, tendon rupture, aortic rupture, psychiatric effects, and hypoglycemia. Consequently, the
use of fluoroquinolones should be avoided when alternative
agents are available.
Our study is not without limitations. We only included
patients with exposure to 1 antimicrobial agent throughout
their entire hospitalization. This is not representative of typical clinical scenarios where changes in treatment occur when
moving from empiric to definitive therapy and where combination therapy may be used [46]. In fact, antibiotic treatment
may be misclassified in as many as 86% of patients when traditional exposure definitions are used [46]. Therefore, our exposure definition allowed us to attribute clinical outcomes to
a single antibiotic, rather than overlooking other antibiotic
exposures, including varying periods of combination therapy,
overlapping therapy, and changes in therapy, which commonly
occurs in other studies. A known limitation of observational
studies is the inability to control for all factors that contribute
to confounding by indication, as providers might not typically
initiate nafcillin or oxacillin therapy empirically. Confounding
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